Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality. Cigarette smoke is the cause of COPD. However, only a fraction of current and/or former smokers develop an increased immune response in the lungs that has a role in COPD progression correlating with lungs infiltration by innate and adaptive immune cells. Both cellular and antibody-mediated autoimmunity can induce COPD in experimental models. In particular, carbonyl-modified proteins modulate autoimmunity in lungs resulting in airways abnormalities and pulmonary emphysema. Although a role for autoimmunity in COPD patients is known, a cause-and-effect relationship between autoimmunity and the mechanisms of COPD has to be proven. In addition, the role of autoimmune responses in the pathogenesis of COPD exacerbations is still unclear. Several drugs targeting autoimmune responses are available and the results of clinical trials are awaited. Finally, specific serum autoantibodies could be used as biomarkers to predict clinical phenotypes or progression of stable COPD.

Role of autoimmunity in the pathogenesis of chronic obstructive pulmonary disease and pulmonary emphysema

Vincenzo Casolaro;Ramapraba Appanna;Gaetano Caramori
2022-01-01

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality. Cigarette smoke is the cause of COPD. However, only a fraction of current and/or former smokers develop an increased immune response in the lungs that has a role in COPD progression correlating with lungs infiltration by innate and adaptive immune cells. Both cellular and antibody-mediated autoimmunity can induce COPD in experimental models. In particular, carbonyl-modified proteins modulate autoimmunity in lungs resulting in airways abnormalities and pulmonary emphysema. Although a role for autoimmunity in COPD patients is known, a cause-and-effect relationship between autoimmunity and the mechanisms of COPD has to be proven. In addition, the role of autoimmune responses in the pathogenesis of COPD exacerbations is still unclear. Several drugs targeting autoimmune responses are available and the results of clinical trials are awaited. Finally, specific serum autoantibodies could be used as biomarkers to predict clinical phenotypes or progression of stable COPD.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11386/4852154
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact